MN-001 (Tipelukast)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MN-001 (Tipelukast), covering 2026-01-23 to 2026-01-23. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]